Sanzyme Biologics

What Sanzyme Biologics does

Sanzyme Biologics Private Limited is a Hyderabad-based fermentation biotechnology company that manufactures and supplies probiotic strains, enzymes, and nutritional ingredients to business customers globally. Founded in 1969 as Uni-Sankyo — an Indo-Japanese joint venture with Sankyo Corporation (now Daiichi Sankyo) — the company received its foundational Bacillus coagulans fermentation technology in 1972, began manufacturing in 1974, and became an independent entity named Sanzyme in 2011 after demerging from Daiichi Sankyo. The fermentation business was subsequently spun out as Sanzyme Biologics in 2017 to focus on the global ingredients market.

The company's core product platform centers on four proprietary spore-forming probiotic strains — SNZ 1969® (Bacillus coagulans), SNZ 1971® (Bacillus clausii), SNZ 1972® (Bacillus subtilis), and SNZ 1986® (Saccharomyces boulardii) — backed by 30+ clinical studies, 150+ million doses consumed annually, and multi-jurisdiction regulatory approvals including US FDA GRAS (GRN 597), Health Canada NPN, ANVISA, and FSANZ. Fermentation capacity exceeds 350,000 liters, with a dedicated NSF-certified facility producing 160 metric tonnes per month of Bacillus coagulans, which the company describes as among the largest globally. The portfolio also includes the patented SNZ TriBac® blend, PetGermina™ for pet food, fermentation-derived Chymosin (2022) and Vitamin K2 (2023), white-label probiotic oral suspensions, and a broad aquaculture and poultry product range.

The revenue model combines branded ingredient sales to global food, supplement, and pharmaceutical formulators, white-label and contract manufacturing services, and direct pharmaceutical distribution in India via the Sporlac brand (8 million+ annual prescriptions). Go-to-market is enterprise B2B via a distributor network spanning the USA, Europe, Asia, and the Middle East, supplemented by direct sales for contract manufacturing and white-label deals. Customer segments span Food & Supplements, Pharmaceuticals, Pet Food, Aquaculture, Poultry, and Environment & Agriculture, with pricing conducted on a quote basis for custom formulations and contract services.

Name

Sanzyme Biologics

Legal name

Sanzyme Biologics Private Limited

Website

https://sanzymebiologics.com

Company type

Private

Founded year

1969

Operating status

Operating

Headcount range

251–500 employees

Short description

Sanzyme Biologics is a Hyderabad-based fermentation biotech company manufacturing proprietary probiotic strains, enzymes, and nutritional ingredients for global food, supplement, pharmaceutical, pet food, aquaculture, and poultry industries.

Ownership category

akta.pro rank

Product category

Probiotic Ingredient Manufacturing

NAICS

Food Manufacturing (311)

SIC

Food And Kindred Products (2000)

akta.pro primary industry

Cultures, Probiotics & Fermentation Ingredients (Starter Cultures, Yeast, Adjuncts) (CRADAOAI)

akta.pro secondary industries

Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery) (HLAAAFAJ), Fermentation Nutrients & Media (Yeast Extracts, Peptones, Nitrogen Sources, Minerals) (AFAJAJAH), Probiotic, Prebiotic & Gut-Health Foods Manufacturing (Fermented Functional Foods, Synbiotics) (AFAKAJAH)

Keywords

• Probiotic manufacturing
• Fermentation technology
• Probiotic strains
• Enzyme production
• Contract research manufacturing

Headquarters

HQ city

Hyderabad

HQ country

India

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Probiotic Ingredient Sales: Sale of branded probiotic strains (SNZ 1969®, SNZ 1971®, SNZ 1972®, SNZ 1986®) and probiotic ingredients to external partners including food, supplement, and pharmaceutical companies globally.
2. Contract Research & Manufacturing: Provides fermentation capacity and expertise for clients requiring probiotic strain development, enzyme production, peptide manufacturing, and microbial food ingredients. Services include scaling up from lab to commercial production.
3. Enzymes and Nutritional Ingredients: Production and sale of fermentation-derived enzymes and nutritional ingredients including chymosin and natural vitamin K2 for food and pharmaceutical applications.
4. Pharmaceutical Probiotic Products: Manufacturing and supply of probiotic strains and oral suspensions (Bacillus coagulans, Bacillus clausii) for pharmaceutical use as Active Pharmaceutical Ingredients (API) meeting cGMP standards.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

Sanzyme Biologics manufactures and supplies proprietary spore-forming probiotic strains and fermentation-derived products (enzymes, nutritional ingredients) to B2B customers across food & supplements, pharmaceuticals, pet food, aquaculture, poultry, and environment & agriculture. The company operates large-scale fermentation facilities producing branded strains including SNZ 1969® (Bacillus coagulans), SNZ 1971® (Bacillus clausii), SNZ 1972® (Bacillus subtilis), SNZ 1986 (Saccharomyces boulardii), and the patented SNZ TriBac® blend. It also offers contract research and manufacturing services leveraging 50+ years of fermentation expertise.

Product overview

Sanzyme Biologics is a fermentation-based biotechnology company offering a portfolio of branded probiotic strains, patented probiotic combinations, and fermentation-derived products. The core offerings include four main probiotic strains: SNZ 1969® (Bacillus coagulans), SNZ 1971® (Bacillus clausii), SNZ 1972® (Bacillus subtilis), and SNZ 1986 (Saccharomyces boulardii), which are available as standalone ingredients or combined in the patented SNZ TriBac® blend. These strains serve multiple market segments including Food & Supplements, Pharmaceuticals (including oral suspensions), Pet Food (alongside PetGermina™), Aquaculture (with products like UNI CLEAR, UNI ECOSENSE, UNI MAX, UNI NUTRICH PLUS, and SANERO AMMONOX), and Poultry. The company also provides Contract Research & Manufacturing services leveraging over five decades of fermentation expertise. Products are sold as ingredients to external partners and manufactured at NSF-certified facilities in Hyderabad, India.

Differentiator

Problem solved

Functional benefit

Brands

• SNZ 1969®: Branded probiotic strain of Bacillus coagulans, well-characterized and clinically studied with over 50 years of history and 150+ million doses annually in 40+ countries
• Sporlac
• PetGermina™
• SNZ TriBac®
• Sanchym

Products and services

• SNZ 1969® (Bacillus coagulans SNZ 1969®) A well-characterized, clinically studied spore-forming probiotic strain with over 50 years of history, used in food, supplements, and pharmaceuticals. GRAS notified in the US, licensed in Canada, and approved in Brazil and Australia/New Zealand.
• SNZ 1971® (Bacillus clausii SNZ 1971®) A spore-forming, clinically studied probiotic strain that survives gastric acid and becomes metabolically active in the intestines. Self-affirmed GRAS and process-friendly for various product formats.
• SNZ 1972® (Bacillus subtilis SNZ 1972®) A naturally occurring, gram-positive, spore-forming bacterium known for exceptional stability and survivability under heat, acidity, and moisture conditions. Self-affirmed GRAS for dietary supplements and functional foods.
• SNZ 1986 (Saccharomyces boulardii) A non-pathogenic probiotic yeast, hardy, acid-tolerant, and thermotolerant. Genetically distinct from brewer's yeast and different from pathogenic candida species.
• SNZ TriBac® A patented probiotic blend containing Bacillus coagulans SNZ 1969®, Bacillus clausii SNZ 1971®, and Bacillus subtilis SNZ 1972®. Clinically studied, shelf-stable, process-friendly, suitable for food, beverage, and supplement formats.
• PetGermina™ A robust, spore-forming branded probiotic strain suitable for pet nutrition and supplement formats including dry kibble, baked treats, powdered toppers, and soft chews. Clinically studied in dogs and cats.
• Bacillus clausii Oral Suspension A probiotic supplement for safe and effective management of antibiotic-associated diarrhea in adults and children. Available as live spores suspended in 5ml ampoules at 2 billion or 4 billion CFU per ampoule.
• UNI CLEAR A proprietary blend of Rhodococcus species and Rhodobacter photosynthetic bacteria used in aquaculture. Reduces black soil, clears organic matter, and reduces total dissolved solids in pond water.
• UNI ECOSENSE A synergistic blend of 6 Bacillus species for aquaculture. Controls Vibrio loads in water, produces digestive enzymes, and maintains water pH and alkalinity.
• SANERO AMMONOX A synergistic blend of probiotic strains for nitrification and denitrification activities in aquaculture. Speeds up denitrification cycle, converts noxious gases to harmless nitrogen, and reduces ammonia and nitrite levels.
• Prome MOS B A probiotic formulation combining probiotics with MOS and beta glucans for poultry. Enhances digestive activity, optimizes FCR, and provides immunomodulatory effects.
• E-Zyme vet An enzyme supplement for improving feed conversion ratio in broiler and layer birds, eliminating anti-nutritional factors, and improving meat and milk production.
• Contract Research & Manufacturing Services Fermentation-based contract research and manufacturing services including probiotic strain development, enzyme and metabolite production, peptide/intermediary production for pharmaceuticals, and microbial food ingredients/flavors/fragrances.
• Fermentation-derived Chymosin (Sanchym) Fermentation-derived chymosin enzyme for food and pharmaceutical applications.
• Fermentation-derived Natural Vitamin K2 Fermentation-derived natural Vitamin K2 for food, supplement, and pharmaceutical applications.

Named customers5 records

Segments6 records

Ideal customer profiles6 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core.

• Daiichi Sankyo Co. Ltd. (formerly Sankyo Corporation, Japan)coreStrategic or Co-development Partner · 1 January 1969Original technology transfer partner for Bacillus coagulans fermentation technology. Sankyo Corporation (now Daiichi Sankyo) transferred formulation and fermentation technology to Sanzyme Biologics (then Uni Sankyo) in 1973. The company was originally established as Uni-Sankyo, an Indo-Japanese joint venture. The entity delinked from Daiichi Sankyo Japan in 2011 to become independent as Sanzyme.
• Global Distributor NetworkcoreChannel Partner/ Reseller/ DistributorComprehensive network of trusted distributors covering the United States, Europe, Asia, and the Middle East. Partners are selected for their extensive experience in the biotechnology industry, commitment to excellence, and deep knowledge of local markets and regulations.
• Technology and Research PartnerscoreStrategic or Co-development PartnerCollaborative partnerships for developing innovative products and technology solutions. Sanzyme leverages expertise in fermentation process, strain development, and recombinant technologies to work with clients on R&D activities while protecting their intellectual property. Services include taking projects from microliters to metric tons and supplying globally.

Scale indicators7 records

Recent moves7 records

Expansion highlights7 records

Broad incumbents

• Novonesis (formerly Chr. Hansen): World's largest producer of probiotic cultures and enzymes, formed via merger of Novozymes and Chr. Hansen. Directly competes in food, supplement, and animal health probiotic ingredients with significantly broader strain portfolio and global commercial reach.
• Kerry Group: Irish taste and nutrition giant with a sizable probiotics platform (including the acquired Ganeden spore-former franchise). Competes with Sanzyme in probiotic ingredients for food, beverage, and supplement applications via a broader ingredient portfolio.
• ADM (Archer Daniels Midland): Global agribusiness and nutrition major with a probiotic/biotics platform (including Biopolis). Competes broadly in human and animal nutrition probiotic ingredients, leveraging larger scale and direct customer relationships.

Direct peers

• Lallemand: Canadian privately held yeast and bacteria specialist with probiotic, baking, brewing, and animal nutrition divisions. Highly comparable B2B fermentation-derived probiotic and yeast business model targeting food, supplement, and animal-health customers globally.
• Lesaffre: French global leader in yeast and fermentation products, with growing presence in probiotics, enzymes, and human/animal nutrition. Comparable large-scale fermentation infrastructure and B2B ingredient model across food, health, and animal nutrition markets.
• Probi AB: Swedish listed probiotic company developing and licensing clinically documented probiotic strains to food, supplement, and pharma customers. Directly comparable branded-strain licensing model with similar clinical-evidence-driven go-to-market.
• Kemin Industries (incl. BIO-CAT): Global ingredient manufacturer with dedicated probiotics (BIO-CAT) and animal nutrition divisions. Comparable fermentation-based probiotic ingredient offering across human food, supplements, and pet/animal feed end-markets.
• Sabinsa: US-India based branded ingredient manufacturer specializing in probiotics, enzymes, and nutraceuticals. Closely comparable India-rooted fermentation business serving global supplement and food formulators with clinically studied branded ingredients.
• Winclove Probiotics: Dutch probiotic ingredient company producing multi-strain formulations for food, supplement, and pharma applications. Comparable B2B probiotic manufacturer with proprietary strains, clinical backing, and European regulatory registrations.

Emerging players

• Gnosis by Lesaffre: Lesaffre's human nutrition affiliate producing fermentation-derived nutritional ingredients including probiotics, yeast extracts, and vitamins. Comparable fermentation ingredients portfolio with growing overlap in spore-former and gut-health solutions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/SanzymeBiologi1
• Facebookfacebook.com/profile.php
• LinkedInlinkedin.com/company/sanzyme-biologics-pvt-ltd

Compliance13 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sanzyme Biologics